Home » Healthcare » Pharmaceuticals » Solid Tumor Cancer Treatment Market

Solid Tumor Cancer Treatment Market By Indication (Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Others), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Surgical Procedures) – Growth, Future Prospects, And Competitive Analysis, 2019 – 2027

Summary
Table Of Content

Industry Outlook

The solid tumor cancer treatment market is set to grow from US$ 121.3 billion in 2018 to US$ 424.6 billion by 2027 at a compound annual growth rate (CAGR) of 15.0% during the forecast period from 2019 to 2027. According to the latest statistics presented by the World Health Organization (WHO) in 2018, approximately 9.6 million people are estimated to die due to cancer; they also claim that 30 to 50% of cancer can be prevented with early diagnosis and an effective treatment regimen.

Hormonal imbalance and an unhealthy lifestyle increase the risk of breast cancer in the female population worldwide

Breast cancer is currently leading the indications segment of the solid tumor cancer treatment market. The key parameters responsible for its high prevalence rate in the female population worldwide are hormonal imbalance during the menstrual cycle of women, an unhealthy lifestyle, and low or no breastfeeding during a woman’s lifetime. The prevalence rate of lung cancer has seen a substantial rise in the last two decades, owing to an increasing number of cigarette smokers globally and a significant rise in air pollution.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Availability of a generic version at an affordable cost makes chemotherapy popular in cancer treatment

Chemotherapy is presently the largest therapy segment in the solid tumor cancer treatment market. The major factor that makes it popular in cancer treatment is its availability in a generic form at an affordable cost. They are used in combination to gain excellent results in solid tumor cancer treatment. In a span of two decades, biologics such as immunotherapy and targeted therapy have gained tremendous popularity in the treatment of solid tumor cancer. Minimal side effects, excellent therapeutic efficacy, and a favorable reimbursement scenario drive its market growth for the treatment of solid tumor cancers.

Rising prevalence of cancer and domicile of key players together drive the market growth in the North American region

North America currently represents 33.6% of the regional market for solid tumor cancer treatment. The primary factor responsible for its market dominance is the rising prevalence of cancer. According to the latest statistics brought forward by the Center for Disease Control and Prevention (CDC), in a span of 10 years from 2010-2020 in the U.S., the number of new cancer cases will rise by 24% in men, amounting to 1 million cases annually, and by 21% in women, approximately 900,000 cases per year.

The domicile of major players, such as AstraZeneca, Merck & Co., Inc., Amgen, Inc., etc., will further bolster market growth in the region. Europe accounts for 30.2% of the market share on account of the supportive regulatory environment provided by the European Medical Agency (EMA) for the development and sale of pharmacological medicines used in solid tumor cancer treatment. Favorable reimbursement scenarios further consolidate the market’s growth. Asia Pacific, with a share of 19.5%, will register good growth during the forecast period owing to rising public health awareness regarding cancer and its treatment and developing healthcare infrastructure.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Historical and Forecast Period

This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by indication, therapy, and geography.

Pharmaceutical companies spearheading the solid tumor cancer treatment market are AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol-Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Olympus Medical Systems.

Key questions are answered in this report.

Which are the major biopharmaceutical companies actively providing medicines for the treatment of solid tumor cancer?
Which organic and inorganic market growth strategies are being considered for performing market assessments?
What are the disease etiology and prevalence rate of common types of cancer worldwide?
What does biologics consist of, and what will be its CAGR during the growth period?
What is the market size in developed regions such as North America and Europe?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global STCT Market Portraiture
2.2. Global STCT Market, by Indication, 2018 (US$ Bn)
2.3. Global STCT Market, by Therapy, 2018 (US$ Bn)
2.4. Global STCT Market, by Geography, 2018 (US$ Bn)

Chapter 3. Solid Tumor Cancer Treatment (STCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global STCT Market, by Key Players, 2018

Chapter 4. Global Solid Tumor Cancer Treatment (STCT) Market, by Indication
4.1. Overview
4.2. Breast Cancer
4.3. Cervical Cancer
4.4. Colorectal Cancer
4.5. Lung Cancer
4.6. Prostate Cancer
4.7. Others (Brain Tumor, Pancreatic Cancer etc.)

Chapter 5. Global Solid Tumor Cancer Treatment (STCT) Market, by Therapy
5.1. Chemotherapy
5.2. Targeted Therapy
5.3. Immunotherapy
5.4. Hormone Therapy
5.5. Surgical Procedures

Chapter 6. Global Solid Tumor Cancer Treatment (STCT) Market, by Geography
6.1. Overview
6.2. North America STCT Market Analysis, 2017– 2027
6.2.1. North America STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.2.2. North America STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.2.3. North America STCT Market, by Country, 2017 – 2027 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe STCT Market Analysis, 2017 – 2027
6.3.1. Europe STCT Market, by Indication, 2017– 2027 (US$ Bn)
6.3.2. Europe STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.3.3. Europe STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific STCT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.4.2. Asia Pacific STCT Market, by Therapy, 2017– 2027 (US$ Bn)
6.4.3. Asia Pacific STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America STCT Market Analysis, 2017 – 2027
6.5.1. Latin America STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.5.2. Latin America STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.5.3. Latin America STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa STCT Market Analysis, 2017 – 2027
6.6.1. MEA STCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.6.2. MEA STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.6.3. MEA STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AstraZeneca, Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Amgen, Inc.
7.3. B. Braun Melsungen AG
7.4. Bristol Myers Squibb & Company
7.5. Eli Lilly & Company
7.6. F.Hoffman La-Roche Ltd.
7.7. Merck & Co., Inc.
7.8. Novartis
7.9. Pfizer, Inc.
7.10. Olympus Medical Systems

List of Figures

FIG. 1 Solid Tumor Cancer Treatment (STCT) Market: Research Methodology
FIG. 2 STCT: Market Segmentation
FIG. 3 Global STCT Market, by Indication, 2018 (US$ Bn)
FIG. 4 Global STCT Market, by Therapy, 2018 (US$ Bn)
FIG. 5 Global STCT Market, by Geography, 2018 (US$ Bn)
FIG. 6 Attractive Investment Proposition: by Geography, 2018
FIG. 7 Competitive Analysis: Global STCT Market, by Key Players, 2018
FIG. 8 Global Breast STCT Market, 2017 – 2027 (US$ Bn)
FIG. 9 Global Cervical STCT Market, 2017– 2027 (US$ Bn)
FIG. 10 Global Colorectal STCT Market, 2017 – 2027 (US$ Bn)
FIG. 11 Global Lung STCT Market, 2017 – 2027 (US$ Bn)
FIG. 12 Global Prostate STCT Market, 2017 – 2027 (US$ Bn)
FIG. 13 Global Other STCT Market, 2017 – 2027 (US$ Bn)
FIG. 14 Global Chemotherapy Market for STCT, 2017 – 2027 (US$ Bn)
FIG. 15 Global Targeted Therapy Market for STCT, 2017 – 2027 (US$ Bn)
FIG. 16 Global Immunotherapy Market for STCT, 2017 – 2027 (US$ Bn)
FIG. 17 Global Hormone Therapy Market for STCT, 2017 – 2027 (US$ Bn)
FIG. 18 Global Surgical Procedures Market for STCT, 2017 – 2027 (US$ Bn)
FIG. 19 U.S. STCT Market, 2017 – 2027 (US$ Bn)
FIG. 20 Canada STCT Market, 2017 – 2027 (US$ Bn)
FIG. 21 U.K. STCT Market, 2017 – 2027 (US$ Bn)
FIG. 22 Germany STCT Market, 2017– 2027 (US$ Bn)
FIG. 23 Rest of Europe STCT Market, 2017 – 2027 (US$ Bn)
FIG. 24 China STCT Market, 2017 – 2027 (US$ Bn)
FIG. 25 Japan STCT Market, 2017 – 2027 (US$ Bn)
FIG. 26 Rest of Asia Pacific STCT Market, 2017 – 2027 (US$ Bn)
FIG. 27 Brazil STCT Market, 2017 – 2027 (US$ Bn)
FIG. 28 Mexico STCT Market, 2017 – 2027 (US$ Bn)
FIG. 29 Rest of Latin America STCT Market, 2017 – 2027 (US$ Bn)
FIG. 30 GCC STCT Market, 2017 – 2027 (US$ Bn)
FIG. 31 Rest of MEA STCT Market, 2017 – 2027 (US$ Bn)

List of Tables

TABLE 1 Global Solid Tumor Cancer Treatment (STCT) Market Portraiture
TABLE 2 Global STCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 3 Global STCT Market , by Therapy, 2017 – 2027 (US$ Bn)
TABLE 4 Global STCT Market, by Geography, 2017 – 2027(US$ Bn)
TABLE 5 North America STCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 6 North America STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 7 North America STCT Market, by Country, 2017 – 2027 (US$ Bn)
TABLE 8 Europe STCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 9 Europe STCT Market, by Therapy, 2017 – 2027(US$ Bn)
TABLE 10 Europe STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 11 Asia Pacific STCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 12 Asia Pacific STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 13 Asia Pacific STCT Market, by Country/Region, 2017– 2027 (US$ Bn)
TABLE 14 Latin America STCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 15 Latin America STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 16 Latin America STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 17 Middle East and Africa STCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 18 Middle East and Africa STCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 19 Middle East and Africa STCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 20 AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 B. Braun Melsungen AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Bristol Myers Squibb & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Olympus Medical Systems: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Solid Tumor Cancer Treatment Market?

The market for Solid Tumor Cancer Treatment Market is expected to reach US$ 424.6 Bn by 2027.

What is the Solid Tumor Cancer Treatment Market CAGR?

The Solid Tumor Cancer Treatment Market is expected to see significant CAGR growth over the coming years, at 15.0%.

What is the Forecast period considered for Solid Tumor Cancer Treatment Market?

The report is forecasted from 2019-2027.

What is the base year considered for Solid Tumor Cancer Treatment Market?

The base year of this report is 2018.

Who are the major players in this market?

AstraZeneca, Plc., Amgen, Inc., B. Braun Melsungen AG, Bristol-Myers Squibb & Company, Eli Lilly & Company, F. Hoffmann-La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –